Pharma Leaders Clinical Leader of the year 2016
Pharma Leaders 2016 Research has brought about six names as finalists for the coveted & prestigious "Clinical Leader Leader of the year 2016" at the historic 9th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016. The six finalists are the result of our independent survey & in continuation of our pursuit to seek innovations & excellence, Pharma Leaders dont go by name & fame but pure talents, no matter which part of the city the nominee is.Global Healthcare CRO industry is expected to reach USD 45.2 billion by 2022, according to a new report by Grand View Research Inc. With the increasing number of patents expiring, increasing number of partnerships to identify biologics and new compounds and growing R&D costs, drug maker and sponsor companies are under pressure to replace the revenue loss specifically due to generics, which has further made drug development more expensive and complex. Asia Pacific is the fastest growing industry due to the reduced cost it offers in comparison to the U.S and other developed economies. Increasing incidence rate of chronic and lifestyle diseases such as heart disease and diabetes coupled with ease in patient recruitment and available expertise for the clinical trials are few drivers propelling growth of the Asian healthcare CRO market.China and India are projected to witness tremendous growth in the CRO market owing to their treatment naïve patient pool coupled with disease prevalence rate. Furthermore, genetically diverse population, highly qualified English-speaking investigators, well equipped hospitals are other opportunities offered by India for global clinical trials.Moreover, owing to the increasing incidence rates of chronic diseases such as cancer, Alzheimer’s and other infectious diseases in children, government funding has increased, which have led to increasing R&D activities.
Email address *
And the Nominees are... *
Submit
reCAPTCHA
This content is neither created nor endorsed by Google.